MedTrace Logo

Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles

NCT01286051 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-03-20

No results posted yet for this study

Summary

Ovulation induction (OI) using gonadotropins is one of the most widely prescribed treatments of infertility. One common problem encountered while attempting OI using gonadotropins is premature ovulation. The purpose of this study is to examine the effect of a single injection of a medication, called ganirelix, to prevent premature ovulation. Patients will be divided into two groups. In the first group, gonadotropins will be used to stimulate the ovaries. In the second group gonadotropins will be used in addition to a single injection of ganirelix, a gonadotropin releasing hormone (GnRH) antagonist. Pregnancy rates will be compared between groups.

Conditions

  • Compare Pregnancy Rates Between FSH Stimulation and FSH and
  • GnRH Antagonist

Interventions

DRUG

Follistim administration

adminstation of FSH for ovulation induction

DRUG

Follistim plus Ganirelix

Follistim plus single injection of ganirelix

Sponsors & Collaborators

  • Houston Fertility Institute

    lead OTHER

Principal Investigators

  • Ghassan F Haddad, M.D. · Houston Fertility Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01286051 on ClinicalTrials.gov